Board of Directors
Our Board of Directors drives our mission to innovate and lead in the medical device industry. Their diverse expertise in technology development and business leadership combined with their commitment to excellence guide our instrumental in our growth and success.
Meet our outstanding board of directors.
Caitlin cameron, chair and ceo Ms. Cameron is a highly accomplished senior executive with 30 years of cross-industry expertise in the Life Sciences, Biotech, Technology, and IT industries. She is a specialist in building high-performing start-up companies. Previously, she held Chair and CEO positions at several Life Sciences and IT companies, building successful businesses and organizations, creating value, and maximizing potential in a very short period of time. In addition, she has built organizations known for employee satisfaction, including being selected for the 100 Best Places to Work in Washington.
chris rivera, board member: Mr. Rivera has extensive experience in the biotechnology and life science industries and has held executive leadership roles in many successful companies, including Tercica, Cephalon, CentOcor, and Genzyme Therapeutics. He has expertise in building successful life sciences companies, board directorship, business strategy, funding/financing, product launch, manufacturing, distribution, commercial infrastructure, reimbursement, FDA market clearance, licensing, and exit via acquisition and IPO.
Mr. Rivera has a demonstrated track record of success in building and exiting life sciences companies throughout his career. He is the Chairman, CEO, and President of EMulate Therapeutics and was the founder and CEO of Hyperion Therapeutics, which Horizon Pharma acquired in 2015.
Mr. Rivera has extensive early-stage and turnaround experience and success and a proven track record in building successful biotech companies. From 2009 – 2015, Mr. Rivera was the President & CEO of Life Science Washington (formerly Washington Biotechnology & Biomedical Association - WBBA), where he was responsible for building the biotechnology industry in Washington state. While at the WBBA, he oversaw one of Washington’s largest and fastest-growing economic industries, including mentoring more than 400 life science start-up companies and co-founding WINGS – Washington’s Medical Technology angel network.
George gates, md, co-founder and chief medical officer: Dr. Gates is a nationally-recognized clinician and medical researcher in otology, with substantial experience in the diagnosis and treatment of otitis media. Dr. Gates is a renowned otolaryngologist and neurotologist, and is an Emeritus Professor at the University of Washington (UW) and former director of the Virginia Merrill Bloedel Hearing Research Center at the UW. In his career, he has authored over 220 peer-reviewed published research reports, review articles, and clinical concepts in Otology/Neurotology. Dr. Gates is the inventor of our technology.
harris brody, board member: Mr. Brody is a Partner of Blue Fog Capital, a private investment company focused on equity and debt investments in early-stage and lower-middle market companies. Mr. Brody’s transactional experience with Blue Fog Capital, J.P. Morgan, and Prudential Financial includes more than $4 billion of private equity investment and $50 billion of M&A activity across a variety of sectors, including technology, healthcare, consumer and retail, industrials, and real estate. Mr. Brody brings a wide variety of experience in strategy, general management, finance, accounting, and operations to the portfolio companies he works with and partners closely and constructively with management to maximize shareholder value. Previously, Mr. Brody spent time in industry at the Clorox Company in a marketing and general management focused role on the Kingsford Charcoal and Combat Insecticides businesses.
mark moehring, Phd, Co-founder and chief science officer: Dr. Moehring is an industry-recognized leader in the field of medical ultrasound, with over three decades of experience in signal processing and medical ultrasound instrument design. His research and product development focus has been in the field of Doppler ultrasound, with a primary emphasis on diagnostic and therapeutic cranial and otitis media applications. Dr. Moehring is the inventor of 16 issued ultrasound and hemodynamic monitoring technology patents.
marion foote, board member: Ms. Foote is an experienced business executive and consultant who is now fully engaged as a private investor and corporate director. In her corporate career, she ultimately served as Group EVP/CMO for Bank of America. In previous positions, she led an ever-expanding portfolio of specialized financial services and strategic initiatives for First Chicago. She began her consulting career with McKinsey & Company and, in 2001, established her own firm (Randolph Partners), which she subsequently merged into Novantas, where she served as a partner through 2012. Ms. Foote has focused on creating customer and shareholder value throughout her career. Collectively, she has led the development and implementation of analytically-driven strategic initiatives and programs worth billions in bottom-line improvement. Ms. Foote serves on the Boards of Avalara, Inc., Saturna Trust Company, the PeaceHealth St. Joseph Medical Center Foundation, and St. Paul’s Academy. She is a past Director of several other public and private companies, all of which have been successfully sold or merged.